Introduction
Remimazolam is an ultrashort-acting intravenous (IV) benzodiazepine, and in January 2021, South Korea was the second country in the world after Japan to approve its use as a general anesthetic [The use of flumazenil, a benzodiazepine antagonist, is expected to overcome the aforementioned shortcomings associated with remimazolam use [